Compagnie Lombard Odier SCmA’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-14	Closed	-$3K	–	587
2020 Q2	$3K	Hold	14	–	–	﹤0.01%	509
2020 Q1	$2K	Buy	14 +4	+40%	+$529	﹤0.01%	481
2019 Q4	$1K	Hold	10	–	–	﹤0.01%	517
2019 Q3	$1K	Hold	10	–	–	﹤0.01%	523
2019 Q2	$1K	Hold	10	–	–	﹤0.01%	519
2019 Q1	$0	Hold	10	–	–	﹤0.01%	613
2018 Q4	$0	Hold	10	–	–	﹤0.01%	614
2018 Q3	$1K	Hold	10	–	–	﹤0.01%	556
2018 Q2	$1K	Hold	10	–	–	﹤0.01%	592
2018 Q1	$1K	Hold	10	–	–	﹤0.01%	595
2017 Q4	$7K	Hold	10	–	–	﹤0.01%	592
2017 Q3	$3K	Hold	10	–	–	﹤0.01%	673
2017 Q2	$3K	Hold	10	–	–	﹤0.01%	690
2017 Q1	$3K	Hold	10	–	–	﹤0.01%	706
2016 Q4	$6K	Hold	10	–	–	﹤0.01%	771
2016 Q3	$11K	Hold	10	–	–	﹤0.01%	836
2016 Q2	$11K	Hold	10	–	–	﹤0.01%	826
2016 Q1	$13K	Hold	10	–	–	﹤0.01%	867
2015 Q4	$25K	Sell	10 -10	-50%	-$15.4K	﹤0.01%	776
2015 Q3	$22K	Hold	20	–	–	﹤0.01%	686
2015 Q2	$20K	Buy	+20	New	+$21.6K	﹤0.01%	720

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Compagnie Lombard Odier SCmA's NBSE Position: Q3 2020 in Review

Compagnie Lombard Odier SCmA sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2020, closing a stake of 14 shares — an estimated $3K sold.

Compagnie Lombard Odier SCmA first reported a position in NBSE in Q2 2015 and held it in 21 quarters. The position peaked at $25K in Q4 2015. 50 funds tracked by Wall St. Rank hold NBSE as of Q3 2020.

Compagnie Lombard Odier SCmA reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 14 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $3K.
Compagnie Lombard Odier SCmA first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2015 and held it in 21 quarters.
Compagnie Lombard Odier SCmA's NeuBase Therapeutics, Inc. Common Stock position peaked at $25K in Q4 2015.
50 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q3 2020, filed 12 Nov 2020.